LOGIN  |  REGISTER
Astria Therapeutics
Viking Therapeutics

Health Catalyst to Participate in Upcoming Investor Conference

March 07, 2023 | Last Trade: US$3.80 0.06 1.60

SALT LAKE CITY, March 07, 2023 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Bryan Hunt, Chief Financial Officer, and Adam Brown, Senior Vice President of Investor Relations and FP&A, will participate in the 44th Annual Raymond James Institutional Investors Conference, being held in Orlando, including a presentation on Wednesday, March 8, 2023 at 8:05am EST. The replay of the presentation will be available online at https://ir.healthcatalyst.com.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.

Health Catalyst Investor Relations Contact:

Adam Brown
Senior Vice President, Investor Relations and FP&A
+1 (855)-309-6800
This email address is being protected from spambots. You need JavaScript enabled to view it.

Health Catalyst Media Contact:

Tarah Neujahr Bryan
Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page